SCHIZOPHRENIA - Read more. October 1, 2010: INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE RESULTS WITH ITI-002 IN PRE-CLINICAL MODELS OF PARKINSON'S DISEASE - Read more. July 29, 2010...: INTRA-CELLULAR THERAPIES ANNOUNCES THE SUCCESSFUL COMPLETION OF A PHASE IB/II STUDY OF ITI-007 IN PATIENTS WITH SCHIZOPHRENIA - Read more. December 21, 2009: INTRA-CELLULAR THERAPIES... ANNOUNCES THE RESULTS OF A PHASE I PET STUDY FOR ITI-007 FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHIATRIC DISORDERS - Read more. March 10, 2009: INTRA-CELLULAR THERAPIES...

-Myers Squibb Company (NYSE: BMY). "This agreement provides ITI with a portfolio of compounds with potential to be effective treatments for schizophrenia and other therapies.... About Intra-Cellular Therapies Intra-Cellular Therapies, Inc. (ITI) is developing novel drugs for the treatment of schizophrenia, depression, Parkinson's and Alzheimer's disease... technology platform is a small molecule therapeutic for the treatment of Parkinson's disease and other CNS disorders. About Schizophrenia Schizophrenia is a devastating brain disorder...

Read more. Press Room Press Release FOR IMMEDIATE RELEASE INTRA-CELLULAR THERAPIES PRESENTS DATA ON ITS SCHIZOPHRENIA AND COGNITION IN SCHIZOPHRENIA PROGRAMS AT THE 14TH BIENNIAL... WINTER WORKSHOP ON SCHIZOPHRENIA AND BIPOLAR DISORDERS NEW YORK, NY, FEBRUARY 15TH, 2008 -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data... on ITI-007, its first-in-class dual 5HT2A receptor anatagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-002, ITIs family...

receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM), and ITI-722, a low-dose formulation of ITI-007, which are in development for schizophrenia and sleep disorders... are prominent symptoms, including schizophrenia, affective disorders, and Parkinson's disease." ABOUT ITI-007 ITI-007 is an orally available compound which combines potent 5HT2A receptor..., depression is a common co- morbid diagnosis in schizophrenia, being present in over 30% of people with schizophrenia in many studies. ABOUT INTRA-CELLULAR THERAPIES Intra-Cellular...

Read more. Press Room Press Release FOR IMMEDIATE RELEASE INTRA-CELLULAR THERAPIES PRESENTS PRECLINICAL DATA FROM SCHIZOPHRENIA AND SLEEP MAINTENANCE PROGRAMS New York, NY... modulator (DPPM) at a major medical meeting last week. The Company is developing ITI-007 for the treatment of schizophrenia and other related psychiatric conditions. In... believe the large separation between activity at dopamine and serotonin receptors will allow a personalized approach to patient treatment for schizophrenia providing an ability...